Due to the absence of effective biomarkers, the precision therapy of head and neck squamous cell carcinoma (HNSCC) still faces challenge. TP53 is one of the most frequently mutated genes in human cancers including HNSCC. Although studies on the regulation of TP53 gene and p53 protein have been extensively explored, the association of TP53-derived circRNAs with HNSCC progression, along with their regulatory mechanisms, remains unknown. This study identifies a novel circRNA derived from TP53 (circTP53), which is upregulated in HNSCC and associated with poor prognosis. It is demonstrated that circTP53 promotes HNSCC progression in vitro and in vivo. Mechanistically, circTP53 interacts with the deubiquitinase USP10, leading to their mutual stabilization, which enhances USP10's deubiquitinating activity on p53, thereby stabilizing p53. Interaction analysis reveals that intron 9 of circTP53 interacts with 100-399AA of USP10. In tumor cells with wild-type p53, circTP53 suppresses cell viability and inhibits the growth of xenograft tumors, while in tumor cells harboring mutant p53, circTP53 demonstrates the opposite effect, enhancing cell viability and promoting xenograft tumor progression. The identification of circTP53 suggests a new direction for p53 research, and the elucidation of circTP53/USP10/p53 axis may provide a new therapeutic scheme for future precision treatment of HNSCC.
CircTP53/USP10/p53 signaling Axis as a Novel Regulator of Progression and Prognosis of Head and Neck Squamous Cell Carcinoma.
CircTP53/USP10/p53信号轴作为头颈部鳞状细胞癌进展和预后的新型调节因子
阅读:5
作者:Wang Yin, Chang Fen, Li Zinan, Duan Chengcheng, Sun Xiangkai, Wang Siyu, Wei Dongmin, Li Wenming, Qian Ye, Cao Shengda, Zhao Juan, Lei Dapeng
| 期刊: | Advanced Science | 影响因子: | 14.100 |
| 时间: | 2025 | 起止号: | 2025 Aug;12(30):e14961 |
| doi: | 10.1002/advs.202414961 | 靶点: | P53 |
| 研究方向: | 信号转导、细胞生物学 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
